Calendar

Week of Apr 27, 2026

Apr 27, 2026phase 1 completion116d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

Therapy area: Immunology. Indication: Unspecified Immunological Disorders

full page →PTC-844 →source: globaldata

Apr 27, 2026phase 1 completion116d agoFortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

full page →balinatunfib →source: globaldata

Apr 27, 2026phase 1 initiation116d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

Therapy area: Immunology. Indication: Liver Transplant Rejection

full page →fostamatinib →source: globaldata

Apr 27, 2026phase 1 initiation116d agoCity of Hope — CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] (Phase I Trial Initiation)CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]

Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas

full page →CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] →source: globaldata

Apr 27, 2026phase 1 initiation116d agoNational Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Autologous B7-H3 CAR T

Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor

full page →Autologous B7-H3 CAR T →source: globaldata

Apr 27, 2026phase 1 2 initiation116d agoNational Institutes of Health Clinical Center — azacitidine (Phase I/II Trial Initiation)Onureg

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

full page →Onureg →source: globaldata

Apr 27, 2026phase 1 2 initiation116d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — EBTATE (Phase I/II Trial Initiation)EBTATE

Therapy area: Oncology. Indication: Thyroid Cancer

full page →EBTATE →source: globaldata

Apr 27, 2026phase 1 2 initiation116d agoNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)sacituzumab govitecan

Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer

full page →sacituzumab govitecan →source: globaldata

Apr 27, 2026phase 2 completion116d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →ayurvedic medicine →source: globaldata

Apr 27, 2026phase 2 completion116d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

Therapy area: Infectious Disease. Indication: Salmonella Infections

full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata

Apr 27, 2026phase 2 completion116d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

full page →nivolumab →source: globaldata

Apr 27, 2026phase 2 initiation116d agoShanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)HLX-35

Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer

full page →HLX-35 →source: globaldata

Apr 27, 2026phase 2 initiation116d agoJiangsu Hengrui Pharmaceuticals Co Ltd — HRS-3738 (Phase II Trial Initiation)HRS-3738

Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

full page →HRS-3738 →source: globaldata

Apr 27, 2026phase 2 initiation116d agoWeifang Yidu Central Hospital — liposome bupivacaine (Phase II Trial Initiation)liposome bupivacaine

Therapy area: Oncology. Indication: Lung Cancer

full page →liposome bupivacaine →source: globaldata

Apr 27, 2026phase 2 initiation116d agoNational Cancer Institute US — busulfan (Phase II Trial Initiation)busulfan

Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma

full page →busulfan →source: globaldata

Apr 27, 2026phase 2 initiation116d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

full page →brincidofovir →source: globaldata

Apr 27, 2026phase 2 initiation116d agoJiangsu Hengrui Pharmaceuticals Co Ltd — fruquintinib (Phase II Trial Initiation)fruquintinib

Therapy area: Oncology. Indication: Colorectal Cancer

full page →fruquintinib →source: globaldata

Apr 27, 2026phase 2 initiation116d agoNational Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)cyclophosphamide

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

full page →cyclophosphamide →source: globaldata

Apr 27, 2026phase 2 initiation116d agoChongqing Cancer Hospital — ondansetron (Phase II Trial Initiation)ondansetron ODT

Therapy area: Oncology. Indication: Ovarian Cancer

full page →ondansetron ODT →source: globaldata

Apr 27, 2026phase 2 3 completion116d agoAnthem Biosciences Ltd — berubicin hydrochloride (Phase II/III Trial Completion)berubicin hydrochloride

Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)

full page →berubicin hydrochloride →source: globaldata

Apr 27, 2026phase 3 completion116d agoCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)elranatamab

Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

full page →elranatamab →source: globaldata

Apr 27, 2026phase 3 completion116d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata

Apr 27, 2026phase 3 initiation116d agoZhuhai Qiwei Biotechnology Co Ltd — QA-102 (Phase III Trial Initiation)QA-102

Therapy area: Ophthalmology. Indication: Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

full page →QA-102 →source: globaldata

Apr 27, 2026phase 3 initiation116d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →abatacept →source: globaldata

Apr 27, 2026phase iv trial initiation116d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

Therapy area: Infectious Disease. Indication: Typhoid Fever

full page →typhoid Vi polysaccharide vaccine →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026